MSCI Nordic Countries Index Rises 0.2% to 386.70; Genmab Leads Gains

A 0.2% index move is modest, but the leadership is telling: a single biotech name like Genmab is doing the heavy lifting rather than broad-based participation. That concentration matters for anyone tracking Nordic exposure, since it means the headline gain may not reflect the region's underlying breadth. The telecom sector's outperformance alongside a biotech-led advance suggests defensive and idiosyncratic drivers rather than a unified macro bid. Whether Genmab's move holds or fades — and whether other sectors follow — is the open question.